

## DELIRIUM APPENDICES (Draft for consultation)

### Appendix K: Evidence Summary

| <i>Typical antipsychotics - prevention; hospital setting review; typical antipsychotics vs placebo</i> |                                 |                               |   |   |   |                              |
|--|---------------------------------|-------------------------------|---|---|---|------------------------------|
| <b>Outcome</b>   | <b>Meta-analysis details</b>    | <b>Summary Statistics</b>     | <b>Comments:</b>  | <b>GRADE details:</b>   | <b>GRADE Comments</b>   | <b>GRADE Evidence Rating</b> |
| Incidence of delirium  | 1 trial; 78 patients; from RCT  | RR=0.32 (95%CI 0.12, 0.91)    | There is no significant difference between the haloperidol and placebo groups           | <ul style="list-style-type: none"> <li>• Study quality: Poor - method of assessment of delirium</li> <li>• Directness: Direct</li> <li>• Imprecision: CI crosses appreciable harm/benefit</li> <li>• Inconsistency: consistent</li> <li>• Reporting bias: Adequate</li> </ul> |   | Low                          |
| Incidence of delirium  | 1 trial; 430 patients; from RCT | RR=0.91 (95%CI 0.59, 1.42)    | No significant difference between the haloperidol and placebo groups.                   | <ul style="list-style-type: none"> <li>• Study quality: Good</li> <li>• Directness: Direct</li> <li>• Imprecision: CI crosses appreciable harm/benefit</li> <li>• Inconsistency: consistent</li> <li>• Reporting bias: Adequate</li> </ul>                                    | all pts received proactive geriatric consultation; downgraded by 2 for imprecision  | Low                          |
| Duration of delirium   | 1 trial; 430 patients; from RCT | MD=-6.4 (95%CI -9.38, -3.42)  | Statistically significant fewer days of delirium in the haloperidol group               | <ul style="list-style-type: none"> <li>• Study quality: Poor - some confounding</li> <li>• Directness: Direct</li> <li>• Imprecision: Number of patients &lt; 400</li> <li>• Inconsistency: consistent</li> <li>• Reporting bias: Adequate</li> </ul>                         | MID=1 day; Use of rescue meds may have confounded this outcome; Pts also received proactive geriatric consultation;   | Low                          |
| Severity of delirium   | 1 trial; 430 patients; from RCT | MD=-4.01 (95%CI -5.87, -2.15) | Statistically significant in favour of the haloperidol group on the DRS-R-98(0-39)      | <ul style="list-style-type: none"> <li>• Study quality: Poor - some confounding</li> <li>• Directness: Direct</li> <li>• Imprecision: Number of patients &lt; 400</li> <li>• Inconsistency: consistent</li> <li>• Reporting bias: Adequate</li> </ul>                         | MID=7.8; Severity of delirium (of those who had delirium) may have been confounded by the use of rescue medication. Pts also received proactive geriatric consultation; Results reported for those who had delirium (n=68); a-priori sample size calc=208 | Low                          |
| Length of stay in hospital   | 1 trial; 430 patients; from RCT | MD=-5.5 (95%CI -8.17, -2.83)  | Statistically significantly shorter length of stay in patients who received haloperidol | <ul style="list-style-type: none"> <li>• Study quality: Poor - some confounding</li> <li>• Directness: Direct</li> <li>• Imprecision: Number of patients &lt; 400</li> <li>• Inconsistency: consistent</li> <li>• Reporting bias: Adequate</li> </ul>                         | MID=1; Use of rescue meds may have confounded this outcome; Patients received proactive geriatric consultation  | Low                          |

|                              |                                |                             |                           |   |  |          |
|------------------------------|--------------------------------|-----------------------------|---------------------------|---|--|----------|
| Adverse events (tachycardia) | 1 trial; 78 patients; from RCT | RR=3.15 (95%CI 0.13, 75.12) | No significant difference | <ul style="list-style-type: none"> <li>● Study quality: Poor - method of assessment of delirium</li> <li>● Directness: Direct</li> <li>● Imprecision: CI crosses appreciable harm/benefit</li> <li>● Inconsistency: consistent</li> <li>● Reporting bias: Adequate</li> </ul> |  | very low |
|------------------------------|--------------------------------|-----------------------------|---------------------------|---|--|----------|

***Atypical antipsychotics - prevention; hospital setting review; atypical antipsychotics vs placebo***

| <b><i>Outcome</i></b>      | <b><i>Meta-analysis details</i></b> | <b><i>Summary Statistics</i></b> | <b><i>Comments:</i></b>   | <b><i>GRADE details:</i></b>   | <b><i>GRADE Comments</i></b>  | <b><i>GRADE Evidence Rating</i></b> |
|----------------------------|-------------------------------------|----------------------------------|---|--|---|-------------------------------------|
| Incidence of delirium      | 1 trial; 126 patients; from RCT     | RR=0.35 (95%CI 0.16, 0.77)       | Significantly fewer patients with delirium in the risperidone group | <ul style="list-style-type: none"> <li>● Study quality: Good</li> <li>● Directness: Direct</li> <li>● Imprecision: CI crosses appreciable harm/benefit</li> <li>● Inconsistency: consistent</li> <li>● Reporting bias: Adequate</li> </ul> |   | Moderate                            |
| Length of stay in hospital | 1 trial; 126 patients; from RCT     | MD=0.2 (95%CI -1.66, 2.06)       | No significant difference in length of hospital stay                | <ul style="list-style-type: none"> <li>● Study quality: Good</li> <li>● Directness: Direct</li> <li>● Imprecision: CI crosses MID</li> <li>● Inconsistency: consistent</li> <li>● Reporting bias: Adequate</li> </ul>                      | MID=1; CI crosses both threshold so downgraded by 2 for imprecision | Low                                 |
| Length of stay in ICU      | 1 trial; 126 patients; from RCT     | MD=0.1 (95%CI -0.64, 0.84)       | No significant difference in number of days spent in the ICU        | <ul style="list-style-type: none"> <li>● Study quality: Good</li> <li>● Directness: Direct</li> <li>● Imprecision: CI crosses MID</li> <li>● Inconsistency: consistent</li> <li>● Reporting bias: Adequate</li> </ul>                      | MID=0.5 days  | Low                                 |

***Cholinesterase inhibitors - prevention; hospital setting review; acetylcholinesterase inhibitor vs placebo***

| <b><i>Outcome</i></b>                           | <b><i>Meta-analysis details</i></b>                | <b><i>Summary Statistics</i></b>           | <b><i>Comments:</i></b>  | <b><i>GRADE details:</i></b>  | <b><i>GRADE Comments</i></b>  | <b><i>GRADE Evidence Rating</i></b> |
|---|--|--|--|---|---|-------------------------------------|
| Incidence of delirium                           | 2 trials; 193 patients; from Meta analysis of RCTs | RR=1.11 (95%CI 0.69, 1.79); p=0.84; I2 =0% | No significant difference between the acetylcholinesterase and placebo groups          | <ul style="list-style-type: none"> <li>● Study quality: Poor - incomplete follow up</li> <li>● Directness: Direct</li> <li>● Imprecision: CI crosses appreciable harm/benefit</li> <li>● Inconsistency: consistent</li> <li>● Reporting bias: Adequate</li> </ul> | downgraded by 2 points for imprecision because the CI crosses over both the acceptable benefits/harms threshold | very low                            |
| Duration of delirium                            | 1 trial; 90 patients; from RCT                     | MD=0.3 (95%CI -0.67, 0.07)                 | No significant difference in duration of delirium (end point 28 days)                  | <ul style="list-style-type: none"> <li>● Study quality: Poor - incomplete follow up</li> <li>● Directness: Direct</li> <li>● Imprecision: Number of patients &lt; 400</li> <li>● Inconsistency: consistent</li> <li>● Reporting bias: Adequate</li> </ul>         | MID= 1 day; OIS=260   | Low                                 |
| Length of stay in hospital                      | 1 trial; 90 patients; from RCT                     | MD=0.2 (95%CI -0.1, 0.5)                   | No significant difference in length of hospital stay (endpoint 28 days)                | <ul style="list-style-type: none"> <li>● Study quality: Poor - incomplete follow up</li> <li>● Directness: Direct</li> <li>● Imprecision: Number of patients &lt; 400</li> <li>● Inconsistency: consistent</li> <li>● Reporting bias: Adequate</li> </ul>         | MID: 1 day; More than 20% missing data;   | Low                                 |
| Number of patients discharged to rehab facility | 1 trial; 90 patients; from RCT                     | RR=0.87 (95%CI 0.68, 1.1)                  | No significant difference between the donepezil and placebo groups at endpoint 28 days | <ul style="list-style-type: none"> <li>● Study quality: Poor - incomplete follow up</li> <li>● Directness: Direct</li> <li>● Imprecision: CI crosses appreciable harm/benefit</li> <li>● Inconsistency: consistent</li> <li>● Reporting bias: Adequate</li> </ul> | More than 20% missing data  | Low                                 |

***Cholinesterase inhibitors - prevention; long-term care review; acetylcholinesterase inhibitor vs usual care***

| <b><i>Outcome</i></b> | <b><i>Meta-analysis details</i></b>                  | <b><i>Summary Statistics</i></b> | <b><i>Comments:</i></b>  | <b><i>GRADE details:</i></b>   | <b><i>GRADE Comments</i></b>  | <b><i>GRADE Evidence Rating</i></b> |
|-----------------------|--|----------------------------------|--|--|---|-------------------------------------|
| Incidence of delirium | 1 trial; 230 patients; from RCT-indirect [Community] | RR=0.65 (95%CI 0.5, 0.85)        | Significantly lower incidence of delirium in the rivastigmine group compared with usual care at endpoint 2 years | <ul style="list-style-type: none"> <li>● Study quality: Poor - allocation conceal</li> <li>● Directness: Indirect</li> <li>Setting- Minor, community</li> <li>● Imprecision: CI crosses appreciable harm/benefit</li> <li>● Inconsistency: consistent</li> <li>● Reporting bias: Adequate</li> </ul> | Allocation concealment and blinding unclear   | very low                            |
| Duration of delirium  | 1 trial; 230 patients; from RCT-indirect [Community] | MD=-3.86 (95%CI -4.45, -3.27)    | Duration of delirium was significantly shorter in the rivastigmine group compared with usual care                | <ul style="list-style-type: none"> <li>● Study quality: Poor - some confounding</li> <li>● Directness: Indirect</li> <li>Setting- Minor, community</li> <li>● Imprecision: Number of patients &lt; 400</li> <li>● Inconsistency: consistent</li> <li>● Reporting bias: Adequate</li> </ul>           | MID:1 day;Differential use of rescue medication may have led to some confounding; Duration of delirium (unclear if patients with delirium or a mean across all patients). Results for mean across all patients presented here. Alloc conceal & blinding unclear | very low                            |

***Cholinesterase inhibitors - prevention; long-term care review; acetylcholinesterase inhibitor vs placebo***

| <b><i>Outcome</i></b> | <b><i>Meta-analysis details</i></b>                  | <b><i>Summary Statistics</i></b> | <b><i>Comments:</i></b>   | <b><i>GRADE details:</i></b>  | <b><i>GRADE Comments</i></b>   | <b><i>GRADE Evidence Rating</i></b> |
|-----------------------|--|----------------------------------|---|---|--|-------------------------------------|
| Cognitive impairment  | 1 trial; 230 patients; from RCT-indirect [Community] | MD=-0.21 (95%CI -0.98, 0.56)     | No significant difference in global performance on Clinical Dementia Rating Scale (0-3) | <ul style="list-style-type: none"> <li>● Study quality: Poor - some confounding</li> <li>● Directness: Indirect</li> <li>Setting- Minor, community</li> <li>● Imprecision: CI crosses MID</li> <li>● Inconsistency: consistent</li> <li>● Reporting bias: Adequate</li> </ul> | MID: 0.6; Allocation concealment & blinding unclear; Differential use of rescue medication may have led to some confounding; | very low                            |